About 13% of African Americans carry two copies of the APOL1 gene variants linked to kidney disease, yet most will never know they are at risk until their kidneys are already failing. Standard blood and urine tests catch damage only after it has taken hold. A study published in May 2026 in Nature Medicine now offers something different: a nine-protein blood test that identified which carriers were heading toward kidney failure up to a decade before any conventional warning sign appeared.
The test, called the APOL1 Proteomic Risk Score (APRS), was developed by researchers at Penn Medicine and validated in an independent federal cohort of more than 15,000 people tracked since 1987. Its arrival coincides with the first targeted drug for APOL1-driven kidney disease advancing through clinical trials, creating a predict-and-treat pathway that did not exist three years ago.
What the blood test measures and who it targets
The APRS works by scanning a standard blood draw for nine proteins tied to inflammation, vascular injury, and early tubular damage, biological signals that can flare long before the kidneys’ filtration rate begins to drop. Researchers built the score using plasma proteomics data from Penn Medicine BioBank participants who carried high-risk APOL1 genotypes but whose estimated glomerular filtration rate (eGFR) still looked normal. The composite outcome the score predicts includes a 40% or greater decline in eGFR, progression to kidney failure, or death within 10 years.
The clinical problem the APRS addresses is one of sorting. People who inherit two APOL1 risk variants face sharply elevated odds of kidney disease, but not all of them will develop it. Creatinine-based eGFR and urine albumin, the current screening workhorses, cannot reliably distinguish those who will progress from those who will not. The APRS produces a numerical score that stratifies patients into lower- and higher-risk categories, giving clinicians a more precise picture than genotype status alone.
External validation in a decades-long federal cohort
A score derived from a single hospital’s biobank needs to prove itself elsewhere. The Penn Medicine team tested the APRS against data from the Atherosclerosis Risk in Communities (ARIC) study, a longitudinal cohort funded by the National Heart, Lung, and Blood Institute that has tracked cardiovascular and metabolic health across four U.S. communities since 1987. ARIC’s participant pool is geographically and demographically broader than any single academic center, and its long follow-up window aligns with the 10-year prediction horizon the APRS targets.
In both the Penn Medicine and ARIC cohorts, the APRS was evaluated in 851 individuals whose kidney function appeared normal at baseline. Higher scores correlated with substantially greater risk of the composite outcome even after the researchers adjusted for age, sex, baseline eGFR, and other clinical factors. That the signal held up in an independent dataset separates the APRS from earlier proteomic markers that showed promise in discovery phases but collapsed when tested outside their original populations.
Why the timing matters: APOL1 therapies are advancing
A predictive score is only as useful as the interventions available to act on it. For years, clinicians had no targeted therapy for APOL1-driven kidney disease, which made early identification less actionable. That changed with inaxaplin, a small-molecule inhibitor designed to block the toxic gain-of-function caused by APOL1 risk variants. A Phase 2 clinical trial published in The New England Journal of Medicine in 2023 tested inaxaplin in people with two APOL1 risk variants and proteinuric kidney disease, showing reductions in proteinuria that supported the drug’s mechanism of action. The trial’s design and endpoints are detailed in its ClinicalTrials.gov registration.
If the APRS can flag which carriers are heading toward kidney failure while their filtration rate is still intact, clinicians could start treatment with drugs like inaxaplin or intensify existing measures, including blood pressure control and renin-angiotensin system blockade, before irreversible damage accumulates. That sequence of predicting early and intervening early is the core logic behind the score’s clinical value, and it only became plausible once a targeted therapy entered human testing.
What remains uncertain
No published data yet show what happens when clinicians use the APRS to guide real-time treatment decisions. The score predicts outcomes, but no trial has tested whether acting on a high result, by starting therapy, enrolling patients in trials, or intensifying monitoring, actually reduces kidney failure rates over the following decade. Predictive accuracy and clinical utility are not the same thing, and bridging that gap will require prospective implementation studies.
Cost and accessibility are open questions as well. Plasma proteomic assays require specialized laboratory infrastructure, and no public data address what the APRS would cost per patient or whether it could be deployed in community health centers that serve the populations most affected by APOL1-driven kidney disease. Without answers on reimbursement and scalability, the test could remain confined to academic medical centers even if its predictive power is strong.
Equity concerns are particularly pressing. APOL1 risk variants are concentrated in populations of African ancestry, who already face disproportionate burdens of chronic kidney disease and reduced access to nephrology care. If the APRS and APOL1-targeted therapies are expensive or limited to specialty centers, they risk widening existing disparities rather than narrowing them.
The inaxaplin program, while promising, is still in clinical development. The published trial established proof of concept, but long-term safety data, optimal dosing, and the drug’s effect on hard endpoints like kidney failure and mortality have not yet been reported. If the therapy pipeline stalls, the APRS would still hold value for prognostic counseling and monitoring, but its impact on patient outcomes would be more limited.
How the APRS could reshape APOL1 screening in community clinics
The strongest evidence behind the APRS is the peer-reviewed Nature Medicine study, which provides the derivation cohort, the protein panel, the composite outcome definition, and the external validation in ARIC. The study design is observational and retrospective, not a randomized trial testing whether the score changes outcomes. It can support risk prediction but not causal claims about interventions triggered by the score.
The inaxaplin trial in The New England Journal of Medicine is a separate line of evidence establishing that a targeted APOL1 therapy exists and has documented short-term effects on proteinuria. It does not directly test the APRS, but it provides the clinical context that makes a predictive score actionable. Longer-term results from the ongoing trial program will determine whether the drug can prevent the outcomes the score predicts.
What the APRS represents, at this stage, is a meaningful advance in precision: a nine-protein blood test that can identify, among people with high-risk APOL1 genotypes and apparently normal kidney function, those who are substantially more likely to experience severe decline over the next decade. Whether turning that knowledge into earlier, targeted treatment will measurably improve outcomes remains the next question to answer. But for a population that has historically been underserved by both screening tools and therapeutic options, having a validated way to see trouble coming is no small thing.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
